Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
Key PointsDespite having relatively favorable disease kinetics, patients with relapsed/refractory BL who receive CAR T cells have poor outcomes.Future tria
Related Articles
Tanning
Tanning outside or indoors can have dangerous consequences. Tanning damages your skin cells, speeds up skin aging and can lead to skin cancer. Learn more.
MRD-Guided Approaches Yield Good Results With IsaKRD in MM | ASH Clinical News | American Society of Hematology
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. With measurable residual disease status (MRD) used as guidance, patients with newly…
Acute obstetric coagulopathy: need for innovation
Previously, Collins et al identified distinct coagulopathic changes in a subset of women with severe postpartum hemorrhage (PPH; defined by blood loss >
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Elections – American Society for Radiation Oncology (ASTRO) – American Society for Radiation Oncology (ASTRO)
ASTRO holds annual elections for its Board of Directors.
DBA syndrome 2.0: Rpl11 mouse model revisited
In this issue of Blood Advances, Liu et al present a new mouse model of Diamond-Blackfan anemia (DBA) syndrome (see figure panel A).1 They use…
Elsevier’s Oncology Journal Network Highlights | Elsevier
Welcome to our Elsevier’s Oncology Journal Network Highlights page
Clinical Education Conference
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals…
MATTERHORN: EFS outcomes of durvalumab plus FLOT in GC/GEJC
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the Phase III MATTERHORN study (NCT04592913), evaluating durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin,…
